The IL-17 family in diseases: from bench to bedside.
Huangfu L, Li R, Huang Y, Wang S.
Signal Transduct Target Ther. 2023 Oct 11;8(1):402. doi: 10.1038/s41392-023-01620-3.
Targeting IL-17 and TH17 cells in chronic inflammation.
Miossec P, Kolls JK.
Nat Rev Drug Discov. 2012 Oct;11(10):763-76. doi: 10.1038/nrd3794.
The post-translational regulation of 17,20 lyase activity.
Miller WL, Tee MK.
Mol Cell Endocrinol. 2015 Jun 15;408:99-106. doi: 10.1016/j.mce.2014.09.010. Epub 2014 Sep 16.
IL-17 and limits of success.
Omidian Z, Ahmed R, Giwa A, Donner T, Hamad ARA.
Cell Immunol. 2019 May;339:33-40. doi: 10.1016/j.cellimm.2018.09.001. Epub 2018 Sep 17.
A novel homozygous CYP17A1 mutation causes partial 17 alpha-hydroxylase/17,20-lyase deficiency in 46,XX: a case report and literature review.
Chen H, Chen Y, Mao H, Huang H, Lou X.
Blood Press. 2023 Dec;32(1):2195008. doi: 10.1080/08037051.2023.2195008.
Fertility in patients with genetic deficiencies of cytochrome P450c17 (CYP17A1): combined 17-hydroxylase/17,20-lyase deficiency and isolated 17,20-lyase deficiency.
Marsh CA, Auchus RJ.
Fertil Steril. 2014 Feb;101(2):317-22. doi: 10.1016/j.fertnstert.2013.11.011.
The star target in SLE: IL-17.
Yang Y, Yan C, Yu L, Zhang X, Shang J, Fan J, Zhang R, Ren J, Duan X.
Inflamm Res. 2023 Feb;72(2):313-328. doi: 10.1007/s00011-022-01674-z. Epub 2022 Dec 20.
The role of interleukin-17 in inflammation-related cancers.
Zhang X, Li B, Lan T, Chiari C, Ye X, Wang K, Chen J.
Front Immunol. 2025 Jan 21;15:1479505. doi: 10.3389/fimmu.2024.1479505. eCollection 2024.
Retraction Note.
Kowsar Publishing Company.
Iran Red Crescent Med J. 2016 Mar 3;18(3):e43586. doi: 10.5812/ircmj.43586. eCollection 2016 Mar.
IL-17 Control of Cutaneous Immune Homeostasis.
Johnston LA, Nagalla RR, Li M, Whitley SK.
J Invest Dermatol. 2024 Jun;144(6):1208-1216. doi: 10.1016/j.jid.2023.11.016. Epub 2024 Apr 26.
